- Update: Breast cancer vaccine trial begins enrolling people with BRCA1 and PALB2 mutations.
- [No author given]
- FORCE. XRAY. 2023 Jan 9.
- News
- Free Full Text
•• Identifier: NCT04674306: Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 9.)
- Ideaya to Launch PARG Inhibitor Trial in Homologous Recombination Repair-Deficient Cancers.
- [No author given]
- Precision Oncology News. 2023 Jan 9.
- News
- Free Full Text
- Novel combination treatment of CDK 4/6 inhibitors with PARP inhibitors in triple negative breast cancer cells.
- Guney Eskiler G, Ozman Z, Haciefendi A, Cansaran-Duman D.
- Naunyn Schmiedebergs Arch Pharmacol. 2023 Jan 4. doi: 10.1007/s00210-022-02375-4. Epub ahead of print.
- PMID: 36598514
- PubMed abstract
- Source abstract
- Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.
- Nakamura T, Kajihara N, Hama N, Kobayashi T, Otsuka R, Han N, Wada H, Hasegawa Y, Suzuki N, Seino KI.
- J Gynecol Oncol. 2022 Dec 21. doi: 10.3802/jgo.2023.34.e25. Epub ahead of print.
- PMID: 36603850
- PubMed abstract
- Source abstract
- Ideaya Biosciences Files IND With FDA for PARG Inhibitor.
- [No author goven]
- Precision Oncology News. 2022 Dec 12.
- News
- Free Full Text